natgillin/translations-raw huggingface dataset:
The main drawback of such known ski boots is that they must be produced, for being adequate to the size of the foot of the user, in various dimensions: this increases production costs, there being necessary different machines and molds for producing the components in the different dimensions, and moreover there exists the problem of stocking the various sizes, for both the producer and for the seller. 
Glavni nedostatak takvih poznatih cipela za skijanje je da se one moraju proizvesti u raznim dimenzijama da bi odgovarale veličini stopala korisnika, što povećava proizvodne troškove, pri čemu su nužni različiti strojevi i kalupi za proizvodnju komponenata različitih dimenzija, a osim toga postoji i problem pohranjivanja zalihe različitih veličina, kako za proizvođača, tako također i za prodavača.
The method of claim 1, wherein the human patient has not received glatiramer acetate therapy prior to initiation of the treatment. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da čovjek kao pacijent nije primio terapiju glatiramer acetatom prije početka liječenja.
The gun stock according to claim 7, characterized in that said small plate has a front part that is fork-shaped and is adapted to engage said mushroom head; a rear part of the small plate being shaped so as to allow an easy grip and handling of the small plate by the user; said small plate further comprising at least one slot that engages protrusions formed in the structure and acting as stop and retention members for said small plate; said small plate being able to slide between a locking position of said mushroom head and a position in which said front fork-shaped part releases said mushroom head, allowing the separation of said cheek rest from said stock body. 
Kundak u skladu s patentnim zahtjevom 7, naznačen time što navedena mala ploča ima prednji dio (171), koji je viličastog oblika i prilagođen je za međudjelovanje s navedenom gljivastom glavom; gdje je stražnji dio (172) male ploče takvog oblika da korisniku omogući lako hvatanje i rukovanje malom pločom; gdje navedena mala ploča dodatno sadrži najmanje jedan utor (173), koji međudjeluje s izbočinama (33, 34), načinjenim u strukturi, koje djeluju kao elementi za zaustavljanje i zadržavanje navedene male ploče; gdje navedena mala ploča može klizati između zabravljujućeg položaja navedene gljivaste glave i položaja u kojem navedeni prednji viličasti dio otpušta navedenu gljivastu glavu, omogućujući odvajanje navedenog naslona za obraz od navedenog tijela kundaka.
Our studies revealed that dextromethorphan alone has a reflex inhibitory activity. 
Naše studije su pokazale da sam dekstrometorfan djeluje u smislu inhibicije refleksa.
Z is -NH-, or a pharmaceutically acceptable salt, or solvate thereof, and wherein more preferably A1 is selected from the group consisting of substituted phenyl having one or two substituents and substituted pyridyl having one substituent, wherein each substituent is independently selected from the group consisting of halo, cyano, hydroxy, amino, haloalkyl, alkoxy, haloalkoxy, and alkyl. 
Zje -NH-, ili njena farmaceutski prihvatljiva sol ili solvat, i gdje je još poželjnije A' odabran iz grupe koja se sastoji od supstituiranog fenila koji ima jednog ili dva supstituenata 1 supstituiranog piridila koji ima jednog supstituenta, pri čemu je svaki supstituent nezavisno odabran iz grupe koja se sastoji od halo, cijano, hidroksi, amino, haloalkila, alkoksi, haloalkoksi i alkila.
The peptide or the composition for the use of any one of claims 14 to 24, wherein the use is capable of ameliorating at least one of the symptoms associated with Alzheimer's disease or related tauopathies in the subject. 
Metoda in vitro dijagnosticiranja ili probiranja subjekta za prisutnost Alzheimerove bolesti ili odgovarajuće tauopatije, ili za prepoznavanje rizika subjekta za razvijanje Alzheimerove bolesti ili odgovarajuće tauopatije, metoda obuhvaća:
A compound according to one of the claims 1 to 7 for use as 11B-HSD1 inhibitor. 
Spoj prema jednom od zahtjeva 1 do 7 naznačen time da je za uporabu kao inhibitor 11B-HSD1.
The method of item 32 further comprising a sequential dose of 3 mg/kg in the escalating dose regimen. 
KSM za uporabu u skladu s patentnim zahtjevom 13, pri čemu nadalje metoda sadrži sekvencijalnu dozu od 3 mg/kg ThKSM u režimu povećavanja doze.
The compound of formula I or a salt, a N-oxide or a salt of a N-oxide of this compound as claimed in claims 7 for use in the treatment of diabetes mellitus. 
Spoj formule I ili njegova sol ili njegov N-oksid, ili sol od N-oksida toga spoja prema bilo kojem od zahtjeva 6 ili 7, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
cooling the solution until crystals are just visible; if the water content is greater than 3% volume/volume when crystals are just visible, adding acetonitrile to the mixture so that the water content is less than 3% volume/volume; 
C) hlađenje otopine sve dok kristali ne postanu jedva vidljivi; d) ako je volumni udio vode veći od 3% u času kada su kristali jedva vidljivi, dodavanje acetonitrila u smjesu tako da je volumni udio vode manji od 3%;
This particular case is more easily producible, but then, there is a limitation on the increase in temperature conditions of oil production by the temperature stability of the cable, and in this connection it is advisable for use in less adverse conditions of oil production. 
Ovaj je slučaj lakše izvediv, ali tada postoji ograničenje povećanja temperaturnih uvjeta pri proizvodnji nafto pomoću temperaturne stabilnosti kabla, 1 ovakva se veza preporuča koristiti u povoljnijim uvjetima proizvodnje nafte.
All experiments were performed with a CHO cell line producing a protein corresponding to the soluble extracellular portion of the p55 TNF receptor (SwissProt Accession No. 
Svi eksperimenti su provedeni sa staničnom linijom CHO koja proizvodi protein koji odgovara topljivom izvanstaničnom dijelu p55 TNF receptora (SwissProt Accession No.
Alternatively, the formula (I) compounds can be prepared with the procedure comprising the following stages: treatment of the corresponding ketones at position 9, obtained as described in patent application WO 00/06579 with p-toluenesulphonic acid and piperazine hexahydrate, so as to yield the corresponding enamines; 
Alternativno, spojevi formule (I) mogu se dobiti postupcima koji obuhvaćaju slijedeće stupnjeve: a) obrada odgovarajućih ketona na položaju 9, dobivenih kako je opisano u međunarodnoj patentnoj prijavi objavljenoj kao WO 00/06579 s p-tolucnsulfonskom kiselinom i piperazin heksahidratom, kako bi se dobili odgovarajući cnamini;
Process according to one of claims 1 to 5 for preparing the compound of formula 1 in the form of the acid addition salt thereof with p-toluenesulphonic acid, characterised in that the conversion of the compound of formula 4-Br into the amidine of formula 1, in the form of the addition salt thereof with p-toluenesulphonic acid is carried out by adding the compound of formula 4-Br to acid-containing alcohol with the addition of p-toluenesulphonic acid and subsequently adding ammonia solution. 
Postupak u skladu s jednim od zahtjeva 1 do 5 za pripravu spoja formule 1 u obliku njegove kiselinske adicijsko soli s p-toluensulfonskom kiselinom, naznačen time, da je prevođenje spoja formule 4-Br u amidin formule 1, u oblik njegove kiselinske adicijske soli s p-toluensulfonskom kiselinom, provedeno dodavanjem spoja formule 4-Br u alkohol koji sadrži kiselinu uz dodavanje p-toluensulfonske kiseline i neposredno zatim dodavanjem otopine amonijaka.
It will be apparent to the skilled person that these examples are solely for illustrative purposes and must not be considered to limit the invention. 
Stručnjaku će biti jasno da ti primjeri služe samo u svrhu prikaza i ne smiju se smatrati ograničenjem izuma.
the composition has a baseline peroxide value not greater than 5 Meq/kg and upon storage of the composition at 25 °C and 60% RH for a period of 6 months, the composition has a second peroxide value not greater than 8 Meq/kg, 
(a) pripravak ima osnovnu peroksidnu vrijednost ne veću od 5 Meq/kg i nakon skladištenja pripravka na 25 *C i 60% RH kroz period od 6 mjeseci, pripravak ima drugu peroksidnu vrijednost ne veću od 8 Meq/kg,
Use of (a) compound of the formula [I] of claim 24 or a pharmaceutically acceptable salt thereof as an active ingredient and (b) at least one other antitumor compound, in combination, for the production of an antitumor agent. 
Upotreba (a) spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, kao aktivnog sastojka i (b) najmanje još jednog antitumorskog spoja, u kombinaciji, naznačena time što su spoj formule [1] 1 dodatni antitumorski spoj namijenjeni proizvodnji antitumorskog sredstva.
Kit for diagnosing colorectal cancer from a human feces sample, characterized in that the kit comprises at least one pair of PCR primers selected from the pair of primers group consisting of SEQ ID NO: 2-3, SEQ ID NO: 5-6, SEQ ID NO: 8-9 and SEQ ID NO: 11-12. 
Upotreba kompleta u skladu s patentnim zahtjevom 12, naznačena time što se navedene nukleinskokiselinske sonde u (i) ili par nukleinskokiselinskih početnica u (ii) bira iz skupine koju čine SEQ ID NO: 2, SEQ ID NO: 13, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, te SEQ ID NO:12; ili s najmanje 90 % istovjetnosti prema njima.
The method according to claim 1 or 2, wherein the G-CSF is recombinant bovine or human methionyl-G-CSF. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je G-CSF rekombinantni goveđi ili ljudski metionil-G-CSF.
A nucleic acid complex comprising a nucleic acid and a highly branched cyclic dextrin, wherein said highly branched cyclic dextrin is a glucan with a degree of polymerization of 50 to 5000 having an inner branched cyclic structure portion formed from a-1,4-glucoside bonds and at least one a-1,6-glucoside bond, and an outer branched structure portion bound to the inner branched cyclic structure portion. 
Kompleks nukleinske kiseline koji sadrži nukleinsku kiselinu i visoko razgranati ciklički dekstrin, naznačen time, da visoko razgranati ciklički dekstrin je glukan sa stupnjem polimerizacije od 50 do 5000 koji ima udio unutrašnje razgranate cikličke strukture formiran od a-1,4-glukozidnih veza i barem jedne a-1,6-glukozidne veze, te udio vanjske razgranate strukture vezan na udio unutarnje razgranate cikličke strukture.
The process according to claim 1, in which the specific flow rate at which the carbonaceous inducer substrate used in said phase b) is supplied is in the range of 35 to 65 mg of carbonaceous inducer substrate per gram of microorganism per hour. 
Postupak prema jednom od zahtjeva 1 do 7, naznačen time što je specifična brzina protoka pri kojoj se dobavlja ugljični produkcijski supstrat koji se koristi u navedenoj fazi proizvodnje b) u rasponu od 35 do 65 mg ugljičnog supstrata po gramu mikroorganizma na sat.
A pharmaceutical composition for use in the treatment of aqueous or evaporative dry eye disease, a condition that is associated with or causes aqueous or evaporative dry eye disease, or symptoms associated therewith in an individual, the composition being suitable for topical application to an ocular surface, and comprising a therapeutically effective concentration of PRG4 suspended in an ophthalmically acceptable balanced salt solution. 
Farmaceutska kompozicija za primjenu u liječenju nedostatka okularne lubrikacije ili simptoma udruženih sa njim koja sadrži PRG4 ili njegov fragment za lubrikaciju u kombinaciji sa terapijski efikasnom koncentracijom PRG4-inducirajućeg spoja odabranog iz grupe koja se sastoji od androgena, selektivnog modulatora receptora androgena, i analoga androgena, pri čemu navedeni analog androgena je odabran iz grupe koja se sastoji od 17a-metil-17B-hidroksi-2-oksa-5a-androstan-3-ona, 4,5a-dihidrotestosterona, i 19-nortestosterona, pri čemu navedeno liječenje obuhvaća topikalnu administraciju navedenog spoja na okularnu površinu.
The antibody according to any one of Claims 1 to 9 for use according to any one of Claims 14, 16 or 17 or the use according to any one of Claims 15 to 17, wherein the treatment comprises administering the antibody, and further comprises administering to the subject an additional treatment for cancer; preferably wherein the additional treatment for cancer is radiation therapy, chemotherapy, or an additional antibody therapeutic. 
Protutijelo prema bilo kojem od zahtjeva 1 do 9 za uporabu prema bilo kojem od zahtjeva 14, 16 ili 17, ili za uporabu prema bilo kojem od zahtjeva 15 do 17, naznačeno time, da liječenje obuhvaća primjenu protutijela, te nadalje obuhvaća primjenu dodatnog liječenja raka na pojedincu; pri čemu, poželjno dodatno liječenje raka je radijacijska terapija, kemoterapija ili dodatni terapeutik s drugim protutijelom.
The monoclonal antibody or antigen binding fragment of claim 1, which binds to at least one determinant of CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2, CCL18/PARC, and CCL23/MPIF-1 which determinant is located between the CC residues of said CC-chemokine and the last C residue of said chemokine. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje jednu determinantu CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP- 1B, CCL5/RANTES, CCL14/HCC-1, CCL15/HCC-2, CCL18/PARC, i CCL23/MPIF-1 koja se nalazi između CC ostataka navedenih CC-kemokina i posljednjeg C ostatka navedenog kemokina.
from writhings number of writhings 
Broj međunarodne prijave:
A process according to claim 1, characterised in that said foamable composition (7) is applied with a degree of overpacking of less than 100%, preferably of less than 90% and more preferably of less than 80%. 
Postupak prema zahtjevu 1, naznačen time da pjenasti sastav (7) bude nanešen jednim stupnjem prekrivanja pri sprejanju manjem od 100%, pri čemu stupanj prekrivanja sprejanja odgovara: [image] pri čemu gustoća kalupljenja daljnje pjenaste tvari odgovara:
is CH3, R2 is H and R3 is F. A compound or its stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 wherein said compound is selected from the group: or 
2. < Spoj ili njegov stereoizomerni oblik, njegova farmaceutski prihvatljiva sol, solvat ili polimorf prema zahtjevu 1 naznačen time što je navedeni spoj odabran iz skupine koju čine:
Process for manufacturing high solids aqueous suspensions of mineral materials) comprising the steps of: 
(54) Naziv izuma: POSTUPAK PROIZVODNJE SUSPENZIJA MINERALNIH MATERIJALA S VISOKIM UDJELOM
The compound of claim 1, selected from the group consisting of: and or a pharmaceutically acceptable salt or solvate thereof. 
Spoj prema patentnom zahtjevu 1, odabrano iz skupine koja se sastoji od: [image] [image] [image] i [image] ili njegova farmaceutski prihvatljiva sol ili solvat.
The compound of formula (I) as defined in claims 1-9 for use according to claim 10, wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof. 
Spoj formule (I) kao što je utvrđeno u patentnim zahtjevima 1-9 za uporabu sukladno patentnom zahtjevu 10, pri čemu, stanje je giht, rekurentni napad gihta, gihtni artritis, hiperurikemija, hipertenzija, kardiovaskularnu bolest, koronarna bolest srca, Lesch-Nyhan-ov sindrom, Kelley-Seegmiller-ov sindrom, bolest bubrega, kamenac u bubregu, insuficijencija bubrega, inflamacija zgloba, artritis, urolitijaza, plumbizam, hiperparatiroidizam, psorijaza, sarkoidoza, deficijencija hipoksantin-guanin fosforiboziltransferaze (HPRT) ili njihova kombinacija.
at least one collecting line (10) coupled between said at least one mobile suction means and said at least one filtration means; and 
- < najmanje jedan sabirni vod (10) spojen između navedenog najmanje jednog pokretnog usisnog sredstva (3) i navedenog najmanje jednog sredstva za filtriranje (7);
In a preferred embodiment the ring opening reaction is carried out such that a compound having a configuration according to formula (3-a) or a salt thereof is obtained 
Postupak prema zahtjevu 17, naznačen time, da se dobiva spoj koji ima konfiguraciju u skladu sa sljedećom formulom (3-a) ili njegova sol: dronarana e
In addition, the uncontrollable movements become more pronounced. 
Dodatno, nekontrolirani pokreti postaju izrazitiji.
The method of claim 17, wherein the leukemia is an acute myeloid leukemia. 
Spoj za uporabu u skladu s patentnim zahtjevom 20 ili 21, naznačen time što je leukemija akutna mijeloidna leukemija.
when aligned with any of SEQ ID NOs: 77 to 95 using a pairwise alignment algorithm, each moving window of x amino acids from N terminus to C terminus has at least x•y identical aligned amino acids, where x is 30 and y is 0.75, wherein the immunogenic polypeptide has lower toxicity as compared to the E. coli AcfD (orf3526) protein and wherein the immunogenic polypeptide raises a substantially similar immune response in a subject as the E. coli AcfD (orf3526) protein. 
20 do 38, 58 do 76 1 77 do 95 koristeći algoritam za parno svrstavanje, svaki pokretni dio x amino kiselina od N terminala do C terminala ima barem x.y jednako poredanih amino kiselina, gdje x je 30 i y je 0.75, pri čemu imunogenski polipeptid podiže značajno sličan imuni odaziv u subjektu kao E. coli AcfD (orf3526) protein.
reacting the compound of the Formula IX with a compound of the Formula II: in the presence of a suitable base to provide a compound of the Formula X or a salt thereof; and 
(G=0O CH, O uz prisutnost pogodne baze sa svrhom dobivanja spoja sa formulom X ili njegove soli; i
a second insulating plate arranged mainly in parallel with a plane of the walls of the room units connected to the connecting profile, wherein a lower edge of the second insulating plate is arranged inside the third form. 
- > da je druga izolacijska ploča (58) smještena uglavnom paralelno s ravninom stijena (31) prostornih jedinica povezanih na vezni profil, i kod čega je donji rub izolacijske ploče smješten unutar trećeg oblika (35).
The THF was evaporated in vacuo and a mixture of the residue and 6N HCl (3 mL) in MeOH (5 mL) was heated in an oil bath at 80° C. for 20 h. 
THF je isparavan in vacuo i smjesa ostatka i 6N HCI (3 mL) u MeOH (5 mL) je zagrijavana u uljnoj kupelji na 80?C 20 sati.
A compound of Formula III: or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or stereoisomer thereof, wherein 
Spoj Formule I, [image], ili njegova farmaceutski prihvatljiva sol, hidrat, solvat, enantimer ili stereoizomer, naznačen time što:
a first component, being a composition for the preparation of a first colon cleansing solution by admixture with water; 
A) prvu komponentu, koja je pripravak za pripremanje prve otopine za čišćenje debelog crijeva miješanjem s vodom;
isolating chromatin bound by said agent; 
izoliranju kromatina vezanog na navedeno sredstvo;
WO-A-03/0287785 discloses a syringe plunger having a penetrable region which is fusible. 
WO-A-03/0287785 otkriva klip šprice koji ima dio koji se može probušiti i koji se može zalijepiti.
Use of a compound of item1 or 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament in the treatment or prevention of pain or diarrhea. 
Uporaba spoja prema zahtjevu I ili 2 ili njegove farmaceutski prihvatljive soli naznačena time da je za dobivanje lijeka za liječenje ili sprečavanje boli ili proljeva.
A recombinant gram-negative bacterial cell, characterized in that the cell: 
Rekombinantna gram-negativna bakterijska stanica, naznačena time da stanica:
A method according to claim 14, in which the heated wood being impregnated and the wood preservative are heated before transferring them into the impregnating chamber. 
Postupak sukladno bilo kojem od Zahtjeva 4-6, naznačen time što su drvo koje se impregnira i konzervans za drvo zagrijani prije prenošenja istih u impregnacijsku komoru (1).
The composition for use in a method of treating cancer of claim 1, wherein the isolated monomeric platinum complex is: 1,2-ethanediamine(dihydrogen pyrophosphato)platinum(II), or 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platina je: 1,2-etandiamin(dihidrogen pirofosfato)platina(IJ), ili
The insulin conjugate according to claim 1, wherein one end of the polyethylene glycol is linked to the amine group of the amino terminal of beta chain of insulin, and the other end of the polyethylene glycol is linked to an amine group or thiol group of the immunoglobulin Fc region. 
Konjugat inzulina prema patentnom zahtjevu 1, naznačen time što jedan kraj polietilen glikola je vezan za grupu amina amino terminusa beta lanca inzulina, i drugi kraj polietilen glikola je vezan za grupu amina ili tiol grupu Fc regije imunoglobulina.
The medicament or the pharmaceutical composition according to claim 15 for treating vasculitis, wherein the administration to said subject of an effective amount of the medicament or the pharmaceutical composition is in combination with one or more therapeutic agent selected in the group of statins, aspirin, blood coagulants, coumadin and corticoids, azathioprine, methothrexate, cyclophosphamide, anti-B lymphocytes antibodies, anti-TNF alpha antibodies and anti-thymocyte globulin. 
Lijek ili farmaceutski pripravak prema zahtjevu 15 za liječenje vaskulitisa, naznačeni time da se efikasna količina lijeka ili farmaceutskog pripravka daje subjektu u kombinaciji s jednim ili više terapijskih agensa iz skupine statina, aspirina, koagulanti krvi, kumadina i kortikoida, azatioprina, metotreksata, ciklofosfamida, antitijela anti-B limfocita, anti-TNF alfa antitijela i anti-timocit globulina.
wherein material that the balloon is made of allows transfer, through the material, of the gas created when the mixture expands and cures to a foam so that the foam, when cured, substantially fills the intragastric balloon. 
Samoekspandirajući intragastrički balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu je materijal od kojeg je napravljen balon napravljen omogućiti prijenos plina kroz materijal.
The isolated antibody of claim 1, wherein the antibody binds specifically to a protein comprising the amino acid sequence of SEQ ID NO: 2. 
Antitijelo iz bilo kojeg od patentnih zahtjeva 1-5 gdje se aminokiselinska sekvenca spomenutog proteina sastoji od aminokiselinske sekvence u skladu sa SEK ID BR: 2.
is a group selected from 
je skupina odabrana od [image] [image] [image]
The aqueous phase is separated and freeze-dried. The crude product is purified by preparative HPLC (column Vydac 218TP, C18, 250x50 mm, flow 60 ml/min, gradient 10% to 70% CH3CN/0.1% TFA in 120 min, detector UV at 240 nm, collection 55 to 75 min) thereby affording intermediate (11') which is freeze-dried as a white solid. 
Sirovi produkt je čišćen preparativnom HPLC (kolona Vydac 21 &8TP, C18, 250x50 mm, protok 60 mL/min, gradijent 10% do 70% CH;ON/0.1% TEA u 120 min, detektor UV pri 240 nm, sakupljeno od 55 do 75 min) i time je dobiven međuprodukt (11') koji je liofiliziran kao bijela krutina.